TOP > 外国特許検索 > MALARIA VACCINE

MALARIA VACCINE

外国特許コード F160008821
整理番号 (S2015-0054-N0)
掲載日 2016年8月10日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP075275
国際公開番号 WO 2016059911
国際出願日 平成27年9月6日(2015.9.6)
国際公開日 平成28年4月21日(2016.4.21)
優先権データ
  • 特願2014-213247 (2014.10.17) JP
発明の名称 (英語) MALARIA VACCINE
発明の概要(英語) The present invention addresses the problem of providing a malaria vaccine exhibiting a higher protective effect than that of conventional malaria vaccines. The present invention was perfected due to the discovery that, after a recombinant virus other than a baculovirus that includes a gene encoding an amino acid sequence of a malaria antigen, plasmid DNA that has a gene encoding an amino acid sequence of this malaria antigen introduced thereto, or a protein that has an amino acid sequence of this malaria antigen is administered to a patient, administering to the patient a recombinant baculovirus that includes a gene encoding an amino acid sequence of this malaria antigen and a gene encoding an amino acid sequence of DAF results in a high protective effect being exhibited.
従来技術、競合技術の概要(英語) BACKGROUND ART
(Malaria) malaria is, infected with a malaria parasite infection transmitted by the anopheles, infected with 2 million each year, 60 million or more people are dead. An ideal measure malaria infection, inoculation of the vaccine is effective. However, vaccine development has been extensive efforts even though, not yet been put to practical use. Malaria is, has a complex life cycle, life stage in one of the further 1-diverse antigen. These and vaccine development and may be very difficult. Current, a measure for the effect of malaria, the pesticide can be mixed and subjected to treatment in the mosquito net artemisinin-based sleep (ACT: artemisinin-based combination therapy) in. However, mosquitoes herbicide resistance, resistance to artemisinin and also reports the appearance of protozoa, quickly malaria vaccine has been a need to develop (reference: non-patent document 1).
Method (a method of treatment of malaria) the treatment of malaria, particularly malaria vaccine with respect to, the following is reported.
Patent Document 1 (Patent Document 1) is, 'one vertebrate promoter, the promoter of the baculovirus connected to the other of the dual, downstream of the promoter, the viral particle of the component with the at least one gene encoding a protein and may be, at least one immunogenic foreign gene can be coupled with a fusion gene containing characterized, dual, promoter fuzed to a gene transfer vector which includes the structure manufacturing method of the' has been disclosed. However, the patent document 1, 'the configuration of the malaria vaccine of the present invention as well as recombinant baculovirus, decay accelerating factor (DAF) or interleukin 12 (IL-12) carrying a' does not suggest or disclose.
Patent Document 2 (Patent Document 2) is, 'recombinant Autographa californica nuclear polyhedrosis virus (AcNPV) as an active ingredient of the pharmaceutical composition, is the recombinant AcNPV, and at least the polyhedrin promoter and is connected to a dual CAG under control of a promoter containing a fusion gene of any of the following and, the pharmaceutical composition' has been disclosed. However, Patent Document 2 is, 'the configuration of the malaria vaccine of the present invention as well as recombinant baculovirus, carries a DAF' does not suggest or disclose.
Patent Document 3 (Patent Document 3) is, 'virus (a) a nucleotide sequence coding the foreign envelope proteins, the coding sequence of the envelope and (b) operatively connected to the first promoter 1, (c) a nucleotide sequence encoding the antigen protein, (d) The antigen coding sequence is operatively coupled to the first recombinant baculovirus promoters 2' has been disclosed. However, Patent Document 3 is, 'malaria vaccine of the present invention as well as the configuration of the recombinant baculovirus, or DAF be carrying IL-12' does not suggest or disclose.
Non-patent document 2 (non-patent document 2) is, 'Priming-boosting method, after the vaccination with vaccinia vaccine (ChAd63) stimulators (MVA) by the inoculation of the protective effect is malaria infection has reached the 40%' - diones. However, non-patent document 2 is, 'the configuration of the malaria vaccine of the present invention as well as recombinant baculovirus, or DAF IL-12 carries a' does not suggest or disclose.
Non-patent document 3 (non-patent document 3) is, 'FP9-CS(fowlpox virus recombinant virus incorporating CSP) after the vaccination with MVA-CS(vaccinia recombinant virus incorporating CSP to) by the inoculation of the protective effect is malaria infection has reached the 90%' - diones. However, in the method described in non-patent document 3, and the adjuvant used, if the adjuvant was not used, the protective effect is reduced to 35% malaria infection. Further, the non-patent document 3, 'malaria vaccine of the present invention as well as the configuration of the recombinant baculovirus, or DAF be carrying IL-12' does not suggest or disclose.
Thus, the current malaria infection protective effect is insufficient, there can be further improved.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY
  • 発明者(英語)
  • YOSHIDA,Shigeto
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close